...
...
Next Story

Dr Reddy’s seeks nod for phase 3 trial of Russia’s Covid-19 vaccine Sputnik V

The phase 3 trial of Sputnik V, developed by Gamaleya National Research Centre of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), is underway in Russia since September 1 on around 40,000 subjects, a report said.

Updated on: Oct 3, 2020, 18:41:52 IST
Hindustan Times, New Delhi | By
Prefer HTon Google
Advertisement

Dr Reddy’s Laboratories has sought permission from the Drugs Controller General of India’s (DGCI) to conduct the phase 3 human clinical trials of Sputnik V, the Russian vaccine to treat the coronavirus disease (Covid-19), according to news agency PTI.

A nurse shows Russia's "Sputnik-V" vaccine against the coronavirus disease (Covid-19) prepared for inoculation in a post-registration trials stage at a clinic in Moscow, Russia. (Reuters File Photo)
A nurse shows Russia's "Sputnik-V" vaccine against the coronavirus disease (Covid-19) prepared for inoculation in a post-registration trials stage at a clinic in Moscow, Russia. (Reuters File Photo)

Russia’s sovereign wealth fund has reached an agreement with the Hyderabad-based pharmaceutical firm for clinical trials and distribution of its experimental vaccine, which was approved by the Russian government in August.

Follow latest updates on coronavirus here

“The Dr Reddy’s Laboratories has applied to the DCGI seeking permission to conduct phase-3 human clinical trials of the Sputnik V vaccine against Covid-19 developed by Russia. The DCGI will carry out a technical evaluation of the application before giving its approval,” PTI quoted a source as saying.

The phase 3 trial of Sputnik V, developed by Gamaleya National Research Centre of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), is underway in Russia since September 1 on around 40,000 subjects, they added.

Click here for full Covid-19 coverage

“Russia has a good history as far as manufacturing vaccines is concerned; they make good vaccines so we presume this vaccine is good. They have published the first study of 76 patients in the medical journal The Lancet which is showing good effectiveness and good antibody immunity generation,” Dr Balram Bhargava, director general of the Indian Council of Medical Research (ICMR), had said when RDIF and Dr Reddy’s had agreed to collaborate.

(With PTI inputs)

 
Get the latest India News, breaking headlines and real-time updates from across the country. Stay informed about politics, government policies, crime, weather and major national developments.
Get the latest India News, breaking headlines and real-time updates from across the country. Stay informed about politics, government policies, crime, weather and major national developments.
SHARE THIS ARTICLE ON
Hindustantimes wants to start sending you push notifications. Click allow to subscribe